Navigation Links
Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
Date:3/6/2009

Therapure will apply its expertise to the development of an innovative plasma protein resulting from LFB's research

Toronto, Canada and Les Ulis, France (PRWEB) March 6, 2009 -- Thomas Wellner, President and CEO of Therapure BioPharma Inc. and Christian Béchon, President and CEO of LFB S.A. announce that a development services contract has been concluded between Therapure Biopharma Inc. and LFB Biotechnologies, a subsidiary of LFB SA, for the development of a manufacturing method for an innovative plasma therapeutic protein.

Therapure will apply its experience and knowledge in therapeutic protein development to develop a manufacturing process to enable the large scale production of this important biologic for clinical trials. The project, which is being jointly managed by research and development teams from the two companies, is expected to yield a novel treatment for a serious illness which currently has limited treatment options.

"We are pleased that LFB Biotechnologies, a major European player in the therapeutic protein field, has selected Therapure Biopharma for this important work," said Thomas Wellner. "Our development team has extensive knowledge in the area of plasma proteins purification and manufacturing methods and we have already achieved some key milestones in this project."

"We have a strong expertise in the development and manufacture of plasma-derived medicinal products and an important R&D portfolio. We have chosen to identify partners with complementary knowledge and the skills to help us to advance some of our products," said Bernard Pelletier, strategic development program director. "We have recognized the strong technical capabilities of Therapure Biopharma in this area and we are pleased with the progress of the project to date."

About Therapure Biopharma
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma is also a specialist in therapies derived from hemoglobin, a blood protein. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: www.therapurebio.com.

About LFB
LFB is a pharmaceutical group and the first French company in the biotech field. LFB is the fifth largest pharmaceutical company in plasma-derived medicinal products in the world, and the third largest laboratory supplying drugs to hospitals in France. LFB commercializes a wide range of 19 plasma-derived medicinal products, addressing more than 80 pathologies in three therapeutic fields: Immunology, Hemostasis, and Intensive Care. Each year, 500,000 patients are treated with LFB's products for chronic pathologies or for emergency cases. In the biotechnology field, LFB develops monoclonal antibodies and a line of therapeutic proteins through transgenic technology with GTC Therapeutics.

For more information, please visit www.lfb.fr.

Media Contact, Therapure Biopharma Inc.:
Alison Withey
+1 705-788-0080

Media Contact, LFB S.A.:
Sandrine Charrières, Corporate Communications Director
+33 169 827 280

# # #

Read the full story at http://www.prweb.com/releases/Therapure_Biopharma/LFB_Biotechnologies/prweb2192744.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
2. Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
3. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
4. China Biopharma, Inc. Issues Corporate Information Update
5. Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update
6. Wound Management Technologies, Inc. Announces Negotiations to Acquire BioPharma Management Technologies, Inc.
7. Sinobiopharma Reports Highlights of Third Quarter Results for Its Operating Subsidiary, Dong Ying China
8. Keryx Biopharmaceuticals Receives Nasdaq Notification
9. Best Practice Database Provides Key Findings for Biopharma Product Launch Evaluation
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
11. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
(Date:2/10/2016)... ... ... LaserShip, a regional parcel carrier that services the eastern U.S., donated and delivered ... order to aid in the Flint water crisis. In 2014, LaserShip acquired Prestige Delivery ... only 15 miles away from Flint. , “We have deep roots in the local ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... unveiling its revolutionary new 2.0 version at the International Roofing Expo in Orlando, ... power of the world's most advanced weather technology in the hands of consumers, ...
(Date:2/10/2016)... NASHVILLE, Tenn. (PRWEB) , ... February 10, 2016 ... ... by the American Academy of Emergency Medicine , an emergency medicine ... of practice management services . , The American Academy of Emergency Medicine, ...
(Date:2/10/2016)... ... 2016 , ... Emergency rooms provide emergency care to stabilize critical health issues, ... with dental emergencies at risk of losing a tooth or their smiles. Dr. Marine ... Common dental emergencies include:, , Avulsed or knocked-out teeth , ...
(Date:2/10/2016)... CO (PRWEB) , ... February 10, 2016 , ... Dr. ... announce the practice is now accepting new dental patients and families in the North ... exceptional dental care services from cleanings to cosmetic dentistry, and all in the most ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 10, 2016 Puerto ... --> Puerto Rico Healthcare and Life Sciences Report 2016 ... 61 page Puerto Rico Healthcare and Life Sciences Report ... insights into the fifth largest territory in the world for ... medical device and diagnostics manufacturing, and more universities per square ...
(Date:2/10/2016)... 10, 2016 CERS ), Medivation, Inc. ... ) and Celldex Therapeutics, Inc. (NASDAQ: CLDX ). ... Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ) and Celldex Therapeutics, ... Orphan Drug Designations become vitally important in the development of ... drugs and biologics which are defined as those intended for ...
(Date:2/10/2016)... ALBANY, New York , February 10, 2016 ... Share, Growth, Trends and Forecast 2015 - 2023 ", reveals ... a rather slow growth from 2015 to 2023 owing to ... register a meager CAGR of 1.30% during the forecast period, ... 2014 to US$38.9 bn in 2023. --> Antibacterial ...
Breaking Medicine Technology: